Biomarin Pharmaceutical (BMRN) EBT Growth (3y) (2012 - 2026)
Biomarin Pharmaceutical (BMRN) EBT Growth (3y) (2012 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBT Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
84.25% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
32.96% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
28.95% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
20.92% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-49.71% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
12.01% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Biomarin Pharmaceutical |
10.52 Bn |
8.29 Bn |
571.21 Mn |
35.50% |
| Date | Value |
|---|
| Mar 31, 2026 |
35.50% |
| Dec 31, 2025 |
-15.64% |
| Sep 30, 2025 |
-140.01% |
| Jun 30, 2025 |
104.46% |
| Mar 31, 2025 |
21.06% |
| Dec 31, 2024 |
65.68% |
| Sep 30, 2024 |
69.99% |
| Jun 30, 2024 |
110.55% |
| Mar 31, 2024 |
65.63% |
| Dec 31, 2023 |
34.12% |
| Sep 30, 2023 |
38.91% |
| Jun 30, 2023 |
54.32% |
| Mar 31, 2023 |
-17.57% |
| Dec 31, 2022 |
-21.53% |
| Sep 30, 2022 |
-29.94% |
| Jun 30, 2022 |
41.48% |
| Mar 31, 2022 |
65.51% |
| Dec 31, 2021 |
-15.41% |
| Sep 30, 2021 |
-33.47% |
| Jun 30, 2021 |
35.45% |
